Search Results for: NRG1

23 interactions involving NRG1 - neuregulin 1 found:

Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
ADAM19 ADAM metallopeptidase domain 19
  • Invadopodia formation
ADGRA2 adhesion G protein-coupled receptor A2
ASGR2 asialoglycoprotein receptor 2
  • Asparagine N-linked glycosylation
  • Antihemophilic factor, human recombinant
  • Lonoctocog alfa
  • Moroctocog alfa
CD72 CD72 molecule
  • Other semaphorin interactions
CEBPD CCAAT enhancer binding protein delta
  • Transcriptional regulation of white adipocyte differentiation
  • Interleukin-4 and Interleukin-13 signaling
  • HCMV Late Events
DKK4 dickkopf WNT signaling pathway inhibitor 4
  • TCF dependent signaling in response to WNT
  • Negative regulation of TCF-dependent signaling by WNT ligand antagonists
  • Signaling by LRP5 mutants
EGF epidermal growth factor
  • Platelet degranulation
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Downregulation of ERBB2 signaling
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Sucralfate
  • Alpha-Aminobutyric Acid
  • Cholecystokinin
  • Tesevatinib
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1
  • mTORC1-mediated signalling
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
ERBB3 erb-b2 receptor tyrosine kinase 3
  • Tucatinib
ERBB4 erb-b2 receptor tyrosine kinase 4
  • Afatinib
  • Fostamatinib
  • Brigatinib
  • Zanubrutinib
FGFR1 fibroblast growth factor receptor 1
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 in disease
  • Signaling by plasma membrane FGFR1 fusions
  • Palifermin
  • Sorafenib
  • Heparin
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • XL999
  • 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
  • (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
  • 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Selpercatinib
  • Pralsetinib
IKZF4 IKAROS family zinc finger 4
ISG20 interferon stimulated exonuclease gene 20
  • Interferon alpha/beta signaling
  • Uridine monophosphate
JAGN1 jagunal homolog 1
KCNK4 potassium two pore domain channel subfamily K member 4
  • TWIK related potassium channel (TREK)
  • Phase 4 - resting membrane potential
LAPTM4B lysosomal protein transmembrane 4 beta
LIMK1 LIM domain kinase 1
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • EPHB-mediated forward signaling
  • Sema3A PAK dependent Axon repulsion
  • Sema3A PAK dependent Axon repulsion
  • Sema4D induced cell migration and growth-cone collapse
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • Dabrafenib
  • Fostamatinib
LIPF lipase F, gastric type
  • Digestion of dietary lipid
  • Orlistat
  • Undecyl-Phosphinic Acid Butyl Ester
MS4A4A membrane spanning 4-domains A4A
PLP1 proteolipid protein 1
TMEM54 transmembrane protein 54